FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: First tolerability and feasibility results

Angelika Bilger, Martin Immanuel Bittner, Anca L. Grosu, Nicole Wiedenmann, Philipp T. Meyer, Elke Firat, Gabriele Niedermann, Wolfgang A. Weber, Dušan Milanović

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Background: Treatment of recurrent glioblastoma (rGBM) remains an unsolved clinical problem. Reirradiation (re-RT) can be used to treat some patients with rGBM, but as a monotherapy it has only limited efficacy. Chloroquine (CQ) is an anti-malaria and immunomodulatory drug that may inhibit autophagy and increase the radiosensitivity of GBM.

Patients and methods: Between January 2012 and August 2013, we treated five patients with histologically confirmed rGBM with re-RT and 250 mg CQ daily.

Results: Treatment was very well tolerated; no CQ-related toxicity was observed. At the first follow-up 2 months after finishing re-RT, two patients achieved partial response (PR), one patient stable disease (SD), and one patient progressive disease (PD). One patient with reirradiated surgical cavity did not show any sign of PD.

Conclusion: In this case series, we observed encouraging responses to CQ and re-RT. We plan to conduct a CQ dose escalation study combined with re-RT.

Translated title of the contributionFET-PET-basierte Rebestrahlung und Chloroquin bei Patienten mit rezidiviertem Glioblastom: Erste Ergebnisse zu Toleranz und Durchführbarkeit
Original languageEnglish
Pages (from-to)957-961
Number of pages5
JournalStrahlentherapie und Onkologie
Volume190
Issue number10
DOIs
StatePublished - 30 Sep 2014
Externally publishedYes

Keywords

  • Chloroquine
  • Glioblastoma multiforme
  • Radiosensitivity
  • Recurrence
  • Reirradiation

Fingerprint

Dive into the research topics of 'FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: First tolerability and feasibility results'. Together they form a unique fingerprint.

Cite this